A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death
Open accessThe DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
The tumor suppressor gene TP53 is the most frequently mutated gene in cancer. The compound APR‐246 (PRIMA‐1Met/Eprenetapopt) is converted to methylene quinuclidinone (MQ) that targets mutant p53 protein and perturbs cellular antioxidant balance. APR‐246 is currently tested in a phase III clinical trial in myelodysplastic syndrome (MDS). By in vitro , ex vivo, and in vivo models, we show that combined treatment with APR‐246 and inhibitors of efflux pump MRP1/ABCC1 results in synergistic tumor cell death, which is more pronounced in TP53 mutant cells. This is associated with altered cellular thiol status and increased intracellular glutathione‐conjugated MQ (GS‐MQ). Due to the reversibility of MQ conjugation, GS‐MQ forms an intracellular drug reservoir that increases availability of MQ for targeting mutant p53. Our study shows that redox homeostasis is a critical determinant of the response to mutant p53‐targeted cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 2 MK‐571 enhances the anti‐tumor activity of APR‐246 in vivo and ex vivo Growth of Eso26 xenografts (R248W mutant TP53) in mice treated with vehicle, APR‐246 (50 mg/kg), MK‐571 (50 mg/kg), or APR‐246 and MK‐571 for 16 days. P values determined by one‐way ANOVA with Tukey’s correction at day 18, n is indicated in the figure.Kaplan–Meier plot of time to reach 1,400 mm3 tumor volume in mice treated with vehicle, APR‐246 (50 mg/kg), MK‐571 (50 mg/kg), or APR‐246 and MK‐571 for 16 days. Mice that were culled at ethical endpoints prior to reaching a tumor volume of > 1,400 mm3 are marked as censored observations. P values were determined by Log‐rank (Mantel–Cox) test between different treatment groups. n is indicated in the figure.Quantification of Ki67 immunohistochemistry staining of Eso26 xenograft tumors at an early timepoint (5 days) or post‐treatment/late timepoint (> 22 days) after treatment initiation with APR‐246 (50 mg/kg) +/− MK‐571 (50 mg/kg). Dots indicate individual tumors.Quantification of cleaved caspase 3 immunohistochemistry staining of Eso26 xenograft tumors in same tumors as shown in Fig 2C. Dots indicate individual tumors.Representative images of hematoxylin/eosin (H&E) staining and immunostaining of Ki67, cleaved caspase 3 and p53, post‐treatment/late timepoint (> 22 days after treatment initiation) with APR‐246 (50 mg/kg) +/− MK‐571 (50 mg/kg).Growth suppression determined by the ATP‐based CTG assay in colorectal cancer patient‐derived organoids (colo‐PDO) after treatment with APR‐246 +/− MK‐571 (n = 3).IC50 values (µM) APR‐246 +/− 20 μM MK‐571 in indicated PDOs (colo‐PDO or esophageal adenocarcinoma patient‐derived PDO [eso‐PDO]). *P = 0.04, paired t‐test (n = 3 except colo‐PDO2 and eso‐PDO3 where n = 2).Organoid area (in black, left y‐axis) and PI intensity (in red, right y‐axis) of colo‐PDO1 and colo‐PDO2 as determined by image analysis 72 h after treatment with APR‐246 +/− MK‐571 (n = 3).Highest synergy score according to the ZIP model based on growth suppression as shown by CTG assay (ATP‐based) or image analysis (Area and PI) in eso‐PDOs and colo‐PDOs. Scores are shown on a log scale. Score above 0 indicates synergy. Each dot indicates one individual experiment. Data information: TP53 status is indicated. Data are represented as mean ± SEM. See also Fig EV2, Appendix Fig S2 and Appendix Table S2.](https://figures.cochat.ai/paper-figures/7df3289509e14332b66bade13413c882/a-thiol-bound-drug-reservoir-enhances-apr-246-induced-mutant-p53-tumor-cell-figure-2.jpg)











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our data on the ROS-dependent, but most likely TP53-independent mechanism of OvCa cell killing by APR-246 is directly supported by recently published work (21,25).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of a note, the high micromolar concentrations of APR-246 required for OvCa cell killing is consistent with published studies (21,25), and due to intracellular metabolism of the drug to the active product methylene quinuclidinone (MQ)(21).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This model is in keeping with our prior work, and confirmed by others (7, 8, 20), demonstrating that inhibiting cystine uptake with erastin or sulfasalazine synergizes with eprenetapopt both in vitro and in vivo.”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our work supports previous findings reporting that GSH depletion and/or factors that regulate GSH availability are central determinants of eprenetapopt activity in cancer cells (6–8), as opposed to p53 and associated apoptotic machinery.”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our data about ROS-dependent, but most likely TP53-independent mechanism of OvCa cell killing by APR-246 is directly supported by recently published work (17, 21).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [17]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 2×
“Data from the luad, lusc, coad, and esca studies of The Cancer Genom Atlas (TCGA) PanCancer Atlas Studies (Hoadley et al, 2018) were downloaded from cBioportal (Cerami et al, 2012; Gao et al, 2013) (https://www.cbioportal.org/).”
BackgroundMethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 2×
“Data from the luad, lusc, coad, and esca studies of The Cancer Genom Atlas (TCGA) PanCancer Atlas Studies (Hoadley et al, 2018) were downloaded from cBioportal (Cerami et al, 2012; Gao et al, 2013) (https://www.cbioportal.org/).”
BackgroundMethodTietze, F. (1969) · Analytical Biochemistry · doi:10.1016/0003-2697(69)90064-5 · Cited by 6,047 · cited 2×
“GSH measurements were performed as previously described (Tietze, 1969; Eriksson et al, 2009).”
MethodMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419 · cited 1×
“TP53 is the most frequently mutated gene in cancer (Kandoth et al, 2013), and TP53 mutation is associated with chromosomal instability (Donehower et al, 2019) and poor prognosis according to some studies (Olivier et al, 2006; Bally et al, 2014).”
BackgroundNext-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394 · cited 1×
“Higher levels of xCT were indeed associated with higher APR-246 IC50 values, i.e., higher resistance (Appendix Fig S7G), in agreement with data from the DepMap portal with 708 cancer cell lines (Ghandi et al, 2019) (Appendix Fig S7H and I) and a previous study (Liu et al, 2017).”
ResultRequirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 1×
“HCT116 TP53 null and R248W cells were generated by targeted disruption of endogenous WT TP53 or knockin of R248W-mutant TP53 (Bunz et al, 1998).”
BackgroundHoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546 · cited 3×
“Data from the luad, lusc, coad, and esca studies of The Cancer Genom Atlas (TCGA) PanCancer Atlas Studies (Hoadley et al, 2018) were downloaded from cBioportal (Cerami et al, 2012; Gao et al, 2013) (https://www.cbioportal.org/).”
BackgroundMethodTHE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419 · cited 2×
“…R package and the web application tool apply four well-known reference models: Zero interaction potency (ZIP) model (Yadav et al, 2015), the highest single agent (HSA) model (Berenbaum, 1989), Bliss independence model (Bliss, 1939) and Loewe additivity model (Loewe, 1953; Lederer et al, 2018).”
MethodMutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 1×
“Mutant p53 may also in some settings have gain-of-function (GOF) activities that promote tumor growth (Muller & Vousden, 2014).”
BackgroundBerenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
The antioxidant function of the p53 tumor suppressor
Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., & Chumakov, P. M. (2005) · Nature Medicine · doi:10.1038/nm1320 · Cited by 1,121 · cited 1×
“Since p53 has a redox regulatory role (Sablina et al, 2005; Kruiswijk et al, 2015) and its activity is dependent on the redox environment (Hainaut & Milner, 1993; Ueno et al, 1999), separating APR-246 anti-tumor activities mediated 1 Department of Oncology-Pathology, Karolinska Institutet,…”
BackgroundP53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080 · cited 1×
“Since p53 has a redox regulatory role (Sablina et al, 2005; Kruiswijk et al, 2015) and its activity is dependent on the redox environment (Hainaut & Milner, 1993; Ueno et al, 1999), separating APR-246 anti-tumor activities mediated 1 Department of Oncology-Pathology, Karolinska Institutet,…”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 4×
“Treatment of mutant p53expressing cells with PRIMA-1 or APR-246 results in mutant p53 reactivation and cell death (Bykov et al, 2002b).”
BackgroundResultInfluentialSelf-citation(1953) · PubMed · Cited by 942
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Rees, M. G., Seashore-Ludlow, B., Cheah, J. H., Adams, D. J., Price, E. V., Gill, S., Javaid, S., Coletti, M. E., Jones, V. L., Bodycombe, N. E., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1986 · Cited by 898 · cited 1×
“…of the genes with the highest correlation to PRIMA-1 resistance in ovarian cancer cells according to data available through the Cancer Dependency Map (DepMap) (Fig EV1A) (Basu et al, 2013; Seashore-Ludlow et al, 2015; Rees et al, 2016) consistent with our NCI database analysis (Bykov et al, 2002a).”
ResultSynergyFinder 2.0: visual analytics of multi-drug combination synergies
Ianevski, A., Giri, A. K., & Aittokallio, T. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa216 · Cited by 873 · cited 1×
“Synergistic effects by combination treatments in cell lines were determined using the web application tool SynergyFinder 1.0 or 2.0 (https://synergyfinder.fimm.fi/) (Ianevski et al, 2017; Ianevski et al, 2020).”
MethodInfluentialSearching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845 · cited 1×
“Both the SynergyFinder R package and the web application tool apply four well-known reference models: Zero interaction potency (ZIP) model (Yadav et al, 2015), the highest single agent (HSA) model (Berenbaum, 1989), Bliss independence model (Bliss, 1939) and Loewe additivity model (Loewe, 1953;…”
MethodBasu, A., Bodycombe, N. E., Cheah, J. H., Price, E. V., Liu, K., Schaefer, G. I., Ebright, R. Y., Stewart, M. L., Ito, D., Wang, S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.003 · Cited by 833 · cited 2×
“Inhibition of efflux pump MRP1 synergizes with APR-246 ABCC1/MRP1 is one of the genes with the highest correlation to PRIMA-1 resistance in ovarian cancer cells according to data available through the Cancer Dependency Map (DepMap) (Fig EV1A) (Basu et al, 2013; Seashore-Ludlow et al, 2015; Rees et al, 2016) consistent…”
ResultHarnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813 · cited 1×
“…of the genes with the highest correlation to PRIMA-1 resistance in ovarian cancer cells according to data available through the Cancer Dependency Map (DepMap) (Fig EV1A) (Basu et al, 2013; Seashore-Ludlow et al, 2015; Rees et al, 2016) consistent with our NCI database analysis (Bykov et al, 2002a).”
ResultIntegrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, O., Hsu, T.-K., Lichtarge, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.001 · Cited by 710 · cited 1×
“TP53 is the most frequently mutated gene in cancer (Kandoth et al, 2013), and TP53 mutation is associated with chromosomal instability (Donehower et al, 2019) and poor prognosis according to some studies (Olivier et al, 2006; Bally et al, 2014).”
BackgroundSelf-citationPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592 · cited 3×
“…free MQ in APR-246-treated cells is very low and that MQ rapidly travels between various cellular thiol targets, including known targets such as mutant p53 (Lambert et al, 2009), thioredoxin reductase (Peng et al, 2013), thioredoxin, glutaredoxin, and ribonucleotide reductase (Haffo et al, 2018).”
BackgroundSelf-citationThe clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bi√®che, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 589 · cited 1×
“TP53 is the most frequently mutated gene in cancer (Kandoth et al, 2013), and TP53 mutation is associated with chromosomal instability (Donehower et al, 2019) and poor prognosis according to some studies (Olivier et al, 2006; Bally et al, 2014).”
BackgroundJackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588 · cited 1×
“The preferential reactivity of Michael acceptor MQ with soft nucleophiles, for instance thiols, derives from the a,b-unsaturated carbonyl (Jackson et al, 2017).”
BackgroundSynergyFinder: a web application for analyzing drug combination dose–response matrix data
Ianevski, A., He, L., Aittokallio, T., & Tang, J. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx162 · Cited by 530 · cited 1×
“Synergistic effects by combination treatments in cell lines were determined using the web application tool SynergyFinder 1.0 or 2.0 (https://synergyfinder.fimm.fi/) (Ianevski et al, 2017; Ianevski et al, 2020).”
MethodInfluentialThe landscape of cancer cell line metabolism
Li, H., Ning, S., Ghandi, M., Kryukov, G. V., Gopal, S., Deik, A., Souza, A., Pierce, K., Keskula, P., Hernandez, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0404-8 · Cited by 525 · cited 1×
“Indeed, GSH and GSSG are the strongest predictive metabolites for response to PRIMA-1, based on examination of 225 metabolites available in the DepMap portal (Li et al, 2019) (Figs 5B and EV5B).”
BackgroundThioredoxin-dependent Redox Regulation of p53-mediated p21 Activation
Ueno, M., Masutani, H., Arai, R. J., Yamauchi, A., Hirota, K., Sakai, T., Inamoto, T., Yamaoka, Y., Yodoi, J., & Nikaido, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35809 · Cited by 428 · cited 1×
“…a redox regulatory role (Sablina et al, 2005; Kruiswijk et al, 2015) and its activity is dependent on the redox environment (Hainaut & Milner, 1993; Ueno et al, 1999), separating APR-246 anti-tumor activities mediated 1 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden 2…”
BackgroundLehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 2×
“The reversibility of MQ adduct formation is a key aspect of the mechanism of action of APR-246 (Fig 8) which may also in part account for the benign safety profile reported from clinical studies of APR-246 (Lehmann et al, 2012).”
BackgroundSelf-citationRedox modulation of p53 conformation and sequence-specific DNA binding in vitro.
Hainaut, P. L., & Milner, J. (1993) · PubMed · Cited by 404
Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation
Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321 · cited 9×
“Considering that APR-246 can induce lipid peroxidation in tumor cells (Liu et al, 2017), it seems likely that increased intracellular accumulation of toxic byproducts of lipid peroxidation following MRP1 inhibition contributes to the observed synergy.”
BackgroundResultInfluentialSelf-citationLi, X., Francies, H. E., Secrier, M., Perner, J., Miremadi, A., Galeano-Dalmau, N., Barendt, W. J., Letchford, L., Leyden, G. M., Goffin, E. K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05190-9 · Cited by 316 · cited 4×
“The PDO model is considered to have strong predictive value for clinical efficacy of novel cancer therapy (Li et al, 2018).”
BackgroundMethodInfluentialSelf-citationTargeting Multidrug Resistance Protein 1 (MRP1, ABCC1): Past, Present, and Future
Cole, S. P. C. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135959 · Cited by 309 · cited 3×
“MRP1 also has a redox regulatory role by controlling GSH/ GSSG homeostasis through the export of GSH and the oxidized form GSSG (Minich et al, 2006; Cole, 2014).”
BackgroundSoussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305 · cited 1×
“The majority of TP53 mutations are missense mutations which disrupt p53-dependent transcription (Soussi & Wiman, 2015).”
BackgroundSelf-citationTargeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Ogiwara, H., Takahashi, K., Sasaki, M., Kuroda, T., Yoshida, H., Watanabe, R., Maruyama, A., Makinoshima, H., Chiwaki, F., Sasaki, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.009 · Cited by 289 · cited 1×
“Thus, both lipid peroxidation and perturbation of redox homeostasis might contribute to the observed oxidative DNA damage after APR-246 treatment (Liu et al, 2017; Hang et al, 2018; Ogiwara et al, 2019).”
BackgroundSubstrate recognition and transport by multidrug resistance protein 1 (ABCC1)
Deeley, R. G., & Cole, S. P. C. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.036 · Cited by 284 · cited 1×
“MK-571 blocked MRP1 pump activity already after 6-h treatment according to accumulation of MRP1 substrate doxorubicin (Appendix Fig S3C; Deeley & Cole, 2006; Zhang et al, 2016).”
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261 · cited 3×
“MQ has been shown to bind preferentially to Cys124 and Cys277 (Wassman et al, 2013; Zhang et al, 2018) of the 10 cysteine (Cys) residues in the DNA-binding core domain of p53 (Meplan et al, 2000).”
BackgroundInfluentialSelf-citationPRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252 · cited 1×
“APR-246 sensitivity is dependent on the presence of mutant p53, cellular thiol status, and drug accumulation Cells expressing mutant p53 were more sensitive to APR-246 than cells lacking p53 (Appendix Table S1, Figs 5A and EV5A), in agreement with our previous data (Bykov et al, 2005).”
ResultSelf-citationWalerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239 · cited 1×
“…that APR-246 treatment leads to an increased xCT protein level in tumor cells (Ali et al, 2016; Liu et al, 2017; Lisek et al, 2018; Synnott et al, 2018), possibly due to its inhibition of mutant p53-NRF2 complexing and/or its pro-oxidant activities (Walerych et al, 2016; Eriksson et al, 2019).”
BackgroundComputational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L. V., Salehi, F., Lin, D.-W., Chung, B. P., Wesley Hatfield, G., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 223 · cited 2×
“This difference is statistically significant (P = 0.02, unpaired t-test) if FLO-1 (Fig EV1B) with a TP53 mutation at Cys277, one of the cysteines targeted by MQ (Zhang et al, 2018), is excluded.”
BackgroundInfluentialDeciphering p53 signaling in tumor suppression
Mello, S. S., & Attardi, L. D. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.11.005 · Cited by 206 · cited 1×
“The tumor suppressor p53 is a transcription factor that regulates multiple cellular processes including cell cycle arrest, metabolism, redox homeostasis, and cell death in response to cellular stress (Mello & Attardi, 2018).”
BackgroundMinich, T., Riemer, J., Schulz, J. B., Wielinga, P., Wijnholds, J., & Dringen, R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03737.x · Cited by 185 · cited 3×
“We detected a decrease in total GSH + GSSG after MK-571 treatment in several cell lines (Figs 6A and EV6 and Appendix Fig S6A), in agreement with previous studies (Cullen et al, 2001; Hirrlinger et al, 2002; Minich et al, 2006).”
BackgroundResultAPR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183 · cited 4×
“Previous studies have indicated that the dependence of APR-246-induced growth suppression and cell death on mutant p53 varies with cellular background (Tessoulin et al, 2014; Grellety et al, 2015; Mohell et al, 2015; Sobhani et al, 2015; Ali et al, 2016; Liu et al, 2017).”
BackgroundInfluentialSelf-citationOlm, E., Fernandes, A. P., Hebert, C., Rundlöf, A.-K., Larsen, E. H., Danielsson, O., & Björnstedt, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902204106 · Cited by 173 · cited 1×
“Furthermore, it has been suggested that MK-571 treatment inhibits secretion of Cys via MRP1 (Olm et al, 2009).”
BackgroundBykov, V. J. N. (2002) · Carcinogenesis · doi:10.1093/carcin/23.12.2011 · Cited by 172 · cited 4×
“Treatment of mutant p53expressing cells with PRIMA-1 or APR-246 results in mutant p53 reactivation and cell death (Bykov et al, 2002b).”
BackgroundResultInfluentialSelf-citationCysteine, Glutathione, and Thiol Redox Balance in Astrocytes
McBean, G. (2017) · Antioxidants · doi:10.3390/antiox6030062 · Cited by 171 · cited 1×
“Elevated Cys levels are presumably a result of increased activity of xCT, although a contribution of for instance the transsulfuration pathway cannot be excluded (McBean, 2017).”
BackgroundYu, X., & Long, Y. C. (2016) · Scientific Reports · doi:10.1038/srep30033 · Cited by 170 · cited 1×
“Increased xCT protein levels after MK-571 treatment could be interpreted as a response to shifts in the intracellular Cys/CySS and GSH/GSSG ratio, which involves induction of SLC7A11 (xCT) via transactivation by ATF4 and NRF2 (Ishii & Mann, 2014; Yu & Long, 2016).”
BackgroundPeng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170 · cited 3×
“…shown that APR-246 (through MQ) exhibits pro-oxidant activities through depletion of glutathione (GSH) and inhibition of the GSH and thioredoxin (TXN) antioxidant systems (Peng et al, 2013; Tessoulin et al, 2014; Mohell et al, 2015; Haffo et al, 2018; Hang et al, 2018; Mlakar et al, 2019).”
BackgroundSelf-citationPRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166 · cited 3×
“Previous studies have indicated that the dependence of APR-246-induced growth suppression and cell death on mutant p53 varies with cellular background (Tessoulin et al, 2014; Grellety et al, 2015; Mohell et al, 2015; Sobhani et al, 2015; Ali et al, 2016; Liu et al, 2017).”
BackgroundIto, K.-I., Olsen, S. L., Qiu, W., Deeley, R. G., & Cole, S. P. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011246200 · Cited by 166 · cited 3×
“We thank Susan Cole for sharing the MRP1k-pcDNA3.”
MethodInfluentialRedox signalling and transition metals in the control of the p53 pathway
Méplan, C., Richard, M.-J., & Hainaut, P. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00297-x · Cited by 166 · cited 1×
“MQ has been shown to bind preferentially to Cys124 and Cys277 (Wassman et al, 2013; Zhang et al, 2018) of the 10 cysteine (Cys) residues in the DNA-binding core domain of p53 (Meplan et al, 2000).”
BackgroundBally, C., Adès, L., Renneville, A., Sebert, M., Eclache, V., Preudhomme, C., Mozziconacci, M.-J., de The, H., Lehmann-Che, J., & Fenaux, P. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.012 · Cited by 162 · cited 1×
“TP53 is the most frequently mutated gene in cancer (Kandoth et al, 2013), and TP53 mutation is associated with chromosomal instability (Donehower et al, 2019) and poor prognosis according to some studies (Olivier et al, 2006; Bally et al, 2014).”
BackgroundIntegrated analysis of TP53 gene and pathway alterations in the cancer genome atlas
Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, O., Hsu, T.-K., Lichtarge, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.061 · Cited by 150 · cited 1×
“TP53 is the most frequently mutated gene in cancer (Kandoth et al, 2013), and TP53 mutation is associated with chromosomal instability (Donehower et al, 2019) and poor prognosis according to some studies (Olivier et al, 2006; Bally et al, 2014).”
BackgroundSelf-citationHirrlinger, J., Schulz, J. B., & Dringen, R. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10308 · Cited by 142 · cited 2×
“We detected a decrease in total GSH + GSSG after MK-571 treatment in several cell lines (Figs 6A and EV6 and Appendix Fig S6A), in agreement with previous studies (Cullen et al, 2001; Hirrlinger et al, 2002; Minich et al, 2006).”
ResultIshii, T., & Mann, G. E. (2014) · Redox Biology · doi:10.1016/j.redox.2014.04.008 · Cited by 134 · cited 2×
“Increased xCT protein levels after MK-571 treatment could be interpreted as a response to shifts in the intracellular Cys/CySS and GSH/GSSG ratio, which involves induction of SLC7A11 (xCT) via transactivation by ATF4 and NRF2 (Ishii & Mann, 2014; Yu & Long, 2016).”
BackgroundPeng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J., Arnér, E. S., & Wiman, K. G. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.137 · Cited by 134
Self-citationHigh levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy
Eriksson, S. E., Prast-Nielsen, S., Flaberg, E., Szekely, L., & Arnér, E. S. J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.016 · Cited by 128 · cited 1×
“Total glutathione (GSH and GSSG) determination by enzymatic re-cycling assay GSH measurements were performed as previously described (Tietze, 1969; Eriksson et al, 2009).”
MethodSelf-citationp53 as a hub in cellular redox regulation and therapeutic target in cancer
Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123 · cited 2×
“…that APR-246 treatment leads to an increased xCT protein level in tumor cells (Ali et al, 2016; Liu et al, 2017; Lisek et al, 2018; Synnott et al, 2018), possibly due to its inhibition of mutant p53-NRF2 complexing and/or its pro-oxidant activities (Walerych et al, 2016; Eriksson et al, 2019).”
BackgroundMethodInfluentialSelf-citationGlutathione in Ovarian Cancer: A Double-Edged Sword
Nunes, S. C., & Serpa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071882 · Cited by 119 · cited 1×
“Cysteine (Cys), a key building block for GSH synthesis, is imported in the oxidized form CySS by antiporter xCT in exchange for glutamate (Glu) (Nunes & Serpa, 2018).”
BackgroundMutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells
Lisek, K., Campaner, E., Ciani, Y., Walerych, D., & Del Sal, G. (2018) · Oncotarget · doi:10.18632/oncotarget.24974 · Cited by 118 · cited 1×
“…several studies have shown that APR-246 treatment leads to an increased xCT protein level in tumor cells (Ali et al, 2016; Liu et al, 2017; Lisek et al, 2018; Synnott et al, 2018), possibly due to its inhibition of mutant p53-NRF2 complexing and/or its pro-oxidant activities (Walerych et…”
BackgroundRENES, J., DE VRIES, E. E. G., HOOIVELD, G. J. E. J., KRIKKEN, I., JANSEN, P. L. M., & MÜLLER, M. (2000) · Biochemical Journal · doi:10.1042/bj3500555 · Cited by 116 · cited 1×
“MRP1 has been reported to mediate efflux of the cytotoxic lipid peroxidation product 4-hydroxynonenal (4-HNE) as a GSH conjugate (Renes et al, 2000; Cole, 2014).”
BackgroundCarter, R. N., & Morton, N. M. (2015) · The Journal of Pathology · doi:10.1002/path.4659 · Cited by 106 · cited 1×
“C). xCT controls Cys/CySS status and GSH synthesis, but also hydrogen sulfide signaling, taurine production, and protein synthesis (Carter & Morton, 2016).”
BackgroundLiu, D. S. H., Read, M., Cullinane, C., Azar, W. J., Fennell, C. M., Montgomery, K. G., Haupt, S., Haupt, Y., Wiman, K. G., Duong, C. P., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-309770 · Cited by 95 · cited 2×
“While APR-246 at 100 mg/kg strongly inhibited tumor growth and prolonged survival (Liu et al, 2015), we observed no effect of 50 mg/kg APR-246 on tumor volume (Fig 2A and Appendix Fig S2A and B) and survival (Fig 2B).”
BackgroundMethodSelf-citationAdditive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition
Lederer, S., Dijkstra, T. M. H., & Heskes, T. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00031 · Cited by 91 · cited 1×
“…R package and the web application tool apply four well-known reference models: Zero interaction potency (ZIP) model (Yadav et al, 2015), the highest single agent (HSA) model (Berenbaum, 1989), Bliss independence model (Bliss, 1939) and Loewe additivity model (Loewe, 1953; Lederer et al, 2018).”
MethodTight Junction Protein Claudin-2 Promotes Self-Renewal of Human Colorectal Cancer Stem-like Cells
Paquet-Fifield, S., Koh, S. L., Cheng, L., Beyit, L. M., Shembrey, C., Mølck, C., Behrenbruch, C., Papin, M., Gironella, M., Guelfi, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1869 · Cited by 74 · cited 1×
“Derivation and culture of eso-PDO (Li et al, 2018) colo-PDO (Paquet-Fifield et al, 2018) is previously described.”
Self-citationHaffo, L., Lu, J., Bykov, V. J. N., Martin, S. S., Ren, X., Coppo, L., Wiman, K. G., & Holmgren, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31048-7 · Cited by 73 · cited 4×
“…shown that APR-246 (through MQ) exhibits pro-oxidant activities through depletion of glutathione (GSH) and inhibition of the GSH and thioredoxin (TXN) antioxidant systems (Peng et al, 2013; Tessoulin et al, 2014; Mohell et al, 2015; Haffo et al, 2018; Hang et al, 2018; Mlakar et al, 2019).”
BackgroundInfluentialSelf-citationPiperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1
Hang, W., Yin, Z.-X., Liu, G., Zeng, Q., Shen, X., Sun, Q., Li, D., Jian, Y., Zhang, Y.-H., Wang, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0110-2 · Cited by 67 · cited 3×
“…shown that APR-246 (through MQ) exhibits pro-oxidant activities through depletion of glutathione (GSH) and inhibition of the GSH and thioredoxin (TXN) antioxidant systems (Peng et al, 2013; Tessoulin et al, 2014; Mohell et al, 2015; Haffo et al, 2018; Hang et al, 2018; Mlakar et al, 2019).”
BackgroundThioredoxin‐related protein of 14 kDa as a modulator of redox signalling pathways
Espinosa, B., & Arnér, E. S. J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14479 · Cited by 62 · cited 1×
“Imported CySS may be efficiently reduced to Cys by enzymes present in the intracellular compartment (Espinosa & Arner, 2019).”
BackgroundClinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma
Bagnoli, M., Beretta, G. L., Gatti, L., Pilotti, S., Alberti, P., Tarantino, E., Barbareschi, M., Canevari, S., Mezzanzanica, D., & Perego, P. (2013) · BioMed Research International · doi:10.1155/2013/143202 · Cited by 59 · cited 1×
“The efflux transporter multidrug resistance-associated protein 1 (MRP1/ABCC1) mediates drug resistance (Walsh et al, 2010; Bagnoli et al, 2013; Cole, 2014) as it exports both endogenous and xenobiotic molecules conjugated to GSH (Cole, 2014; Whitt et al, 2016).”
BackgroundLigtenberg, M. A., de Coaña, Y. P., Shmushkovich, T., Yoshimoto, Y., Truxová, I., Yang, Y., Betancur-Boissel, M., Eliseev, A. V., Wolfson, A. D., & Kiessling, R. W. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.015 · Cited by 56 · cited 1×
“KADA is a newly established melanoma cell line (Ligtenberg et al, 2018).”
BackgroundAli, D., Mohammad, D. K., Mujahed, H., Jonson‐Videsäter, K., Nore, B., Paul, C., & Lehmann, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14036 · Cited by 49 · cited 2×
“Previous studies have indicated that the dependence of APR-246-induced growth suppression and cell death on mutant p53 varies with cellular background (Tessoulin et al, 2014; Grellety et al, 2015; Mohell et al, 2015; Sobhani et al, 2015; Ali et al, 2016; Liu et al, 2017).”
BackgroundCullen, K. V., Davey, R. A., & Davey, M. W. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00681-5 · Cited by 48 · cited 2×
“We detected a decrease in total GSH + GSSG after MK-571 treatment in several cell lines (Figs 6A and EV6 and Appendix Fig S6A), in agreement with previous studies (Cullen et al, 2001; Hirrlinger et al, 2002; Minich et al, 2006).”
ResultThe effect of glutathione on the ATPase activity of MRP1 in its natural membranes
Hooijberg, J. H., Pinedo, H. M., Vrasdonk, C., Priebe, W., Lankelma, J., & Broxterman, H. J. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01238-2 · Cited by 43 · cited 1×
“However, as MRP1 efflux activity is GSH- and ATP-dependent (Hooijberg et al, 2000), MRP1 protein expression may not necessarily reflect its efflux pump activity.”
BackgroundWalsh, N., Kennedy, S., Larkin, A., Tryfonopoulos, D. J., Eustace, A. J., Mahgoub, T., Conway, C., Oglesby, I. K., Collins, D. M., Ballot, J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605590 · Cited by 43 · cited 1×
“The efflux transporter multidrug resistance-associated protein 1 (MRP1/ABCC1) mediates drug resistance (Walsh et al, 2010; Bagnoli et al, 2013; Cole, 2014) as it exports both endogenous and xenobiotic molecules conjugated to GSH (Cole, 2014; Whitt et al, 2016).”
BackgroundYu, X., Kogan, S., Chen, Y., Tsang, A. T., Withers, T., Lin, H., Gilleran, J., Buckley, B., Moore, D., Bertino, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0822 · Cited by 42 · cited 1×
“This is consistent with data showing that brief exposure of R175H mutant p53 to Zn2+ is sufficient to induce mutant p53 reactivation and apoptosis (Yu et al, 2018).”
BackgroundThe Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
Synnott, N. C., Madden, S. F., Bykov, V. J. N., Crown, J., Wiman, K. G., & Duffy, M. J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.08.009 · Cited by 35 · cited 1×
“…have shown that APR-246 treatment leads to an increased xCT protein level in tumor cells (Ali et al, 2016; Liu et al, 2017; Lisek et al, 2018; Synnott et al, 2018), possibly due to its inhibition of mutant p53-NRF2 complexing and/or its pro-oxidant activities (Walerych et al, 2016; Eriksson…”
BackgroundSelf-citationPRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53
Grellety, T., Laroche-Clary, A., Chaire, V., Lagarde, P., Chibon, F., Neuville, A., & Italiano, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1667-1 · Cited by 32 · cited 1×
“Previous studies have indicated that the dependence of APR-246-induced growth suppression and cell death on mutant p53 varies with cellular background (Tessoulin et al, 2014; Grellety et al, 2015; Mohell et al, 2015; Sobhani et al, 2015; Ali et al, 2016; Liu et al, 2017).”
BackgroundPRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53
Sobhani, M., Abdi, J., Manujendra, S. N., Chen, C., & Chang, H. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1026482 · Cited by 28 · cited 1×
“Previous studies have indicated that the dependence of APR-246-induced growth suppression and cell death on mutant p53 varies with cellular background (Tessoulin et al, 2014; Grellety et al, 2015; Mohell et al, 2015; Sobhani et al, 2015; Ali et al, 2016; Liu et al, 2017).”
BackgroundPRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level
Mlakar, V., Jurkovic Mlakar, S., Lesne, L., Marino, D., Rathi, K. S., Maris, J. M., Ansari, M., & Gumy-Pause, F. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1066-6 · Cited by 25 · cited 3×
“…shown that APR-246 (through MQ) exhibits pro-oxidant activities through depletion of glutathione (GSH) and inhibition of the GSH and thioredoxin (TXN) antioxidant systems (Peng et al, 2013; Tessoulin et al, 2014; Mohell et al, 2015; Haffo et al, 2018; Hang et al, 2018; Mlakar et al, 2019).”
BackgroundZhang, W., Clair, D. K. S., Butterfield, D. A., & Vore, M. E. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw021 · Cited by 23 · cited 1×
“MK-571 blocked MRP1 pump activity already after 6-h treatment according to accumulation of MRP1 substrate doxorubicin (Appendix Fig S3C; Deeley & Cole, 2006; Zhang et al, 2016).”
Jason, D. F., Keeton, A. B., Bernard, D., Larry, A., Sodani, K. S., Zhe-Sheng, C., & Piazza, G. A. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.30.20150108 · Cited by 21
Research works printed but not linked: 1
- 79. Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., Behrenbruch, C., Simpson, K. J., Hollande, F., Abrahmsen, L., Clemons, N. J. & Wiman, K. G. (2020). A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. EMBO MOLECULAR MEDICINE, 13 (2), https://doi.org/10.15252/emmm.201910852. Persistent Link: http://hdl.handle.net/11343/272304 File Description: Published version License:
Cited by
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 190
Fujihara, K. M., Zhang, B. Z., Jackson, T. D., Ogunkola, M. O., Nijagal, B., Milne, J. V., Sallman, D. A., Ang, C.-S., Nikolic, I., Kearney, C. J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm9427 · Cited by 102
“This model is in keeping with our prior work, and confirmed by others ( 7 , 8 , 20 ), demonstrating that inhibiting cystine uptake with erastin or sulfasalazine synergizes with eprenetapopt both in vitro and in vivo.”
InfluentialSelf-citationPharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 93
“…intracellular availability of eprenetapopt is also dependent on cellular redox status, and combination therapy with the xCT inhibitor sulfasalazine or an inhibitor of the MRP1 efflux pump (encoded by ABCC1 ), which modulate the cellular thiol pools, results in synergistic tumour cell death 93,140 .”
Self-citationDegtjarik, O., Golovenko, D., Diskin-Posner, Y., Abrahmsén, L., Rozenberg, H., & Shakked, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-27142-6 · Cited by 78
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids
Choo, N., Ramm, S., Luu, J., Winter, J. M., Selth, L. A., Dwyer, A. R., Frydenberg, M., Grummet, J., Sandhu, S., Hickey, T. E., et al. (2021) · SLAS Discovery · doi:10.1177/24725552211020668 · Cited by 69
Self-citation
Metadata
- Authors
- Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., Behrenbruch, C., Simpson, K. J., Hollande, F., Abrahmsen, L., Clemons, N. J., & Wiman, K. G.
- Affiliations
- Karolinska Institutet (SE)
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- University of Cambridge (GB)
- Corresponding author
- Wiman, Klas G
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-12-14
- Volume
- 13
- Issue
- 2
- Pages
- e10852-e10852
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7863383
- OpenAlex
- W3110888894
- Semantic Scholar
- 90cf97d8adfcfee270b01369013080af9890095b
- Cited by
- 41
- References
- 80
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 8 · 2023: 7 · 2022: 11 · 2021: 6 · 2020: 2
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Vetenskapsrådet (2017‐01509)
- Cancerfonden (18 0774)
- Barncancerfonden (PR2017‐0106)
- Radiumhemmets Forskningsfonder (171213)
- Knut och Alice Wallenbergs Stiftelse
- Aprea Therapeutics
- Karolinska Institutet
- Department of Health, Australian Government | National Health and Medical Research Council (APP1120293, GNT1164081)
- Department of Health and Human Services, State Government of Victoria (MCRF16002)
- Tour de Cure Foundation (RSP ‐ 0004 ‐ 17/18)
- UKRI | Medical Research Council (RG84369)
- Australian Cancer Research Foundation
- Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS) program
- Peter MacCallum Cancer Centre Foundation
- University of Melbourne Research Collaborative Infrastructure Program
- Cancer Research UK (RG81771/84119)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- APR-246, PRIMA-1MET, mutant p53, TP53 mutation, glutathione conjugation, redox homeostasis, cancer cell death, myelodysplastic syndrome
- MeSH terms
- Pharmaceutical Preparations, Humans, Mutation, Neoplasms, Quinuclidines, Sulfhydryl Compounds, Tumor Suppressor Protein p53, Cell Death, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.